In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies

Published:2008-11-18 Issue:2 Volume:26 Page:193-201
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Wiberg Kristina,Carlson Kristina,Åleskog Anna,Larsson Rolf,Nygren Peter,Lindhagen Elin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-008-9107-6.pdf

Reference41 articles.

1. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–22.

2. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006;46:189–213. doi: 10.1146/annurev.pharmtox.46.120604.141300 .

3. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4:290–6.

4. Fisher RI, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74. doi: 10.1200/JCO.2006.07.9665 .

5. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer. 1999;35:424–32. doi: 10.1016/S0959-8049(98)00286-X .

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma;Resistance to Targeted Anti-Cancer Therapeutics;2021

2. Advances & future prospects in newly diagnosed multiple myeloma patients;ADVANCES IN CELL AND GENE THERAPY;2020-07-07

3. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15;PLOS ONE;2019-10-22

4. The role of АВС transporters in drug resistance to bortezomib in multiple myeloma;Advances in molecular oncology;2019-04-28

5. High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity;Analytical Chemistry;2018-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3